Citi analyst Patrick Donnelly downgraded Bio-Rad (BIO) to Neutral from Buy with a price target of $300, down from $375. The firm does not see a recovery path for the company’s process chromatography business, which it views as Bio-Rad’s growth and margin growth engine. Further, the company faces uncertainties in the China diagnostics space, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO: